高リン酸塩血症(Hyperphosphatemia)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hyperphosphatemia Overview 7
Therapeutics Development 8
Pipeline Products for Hyperphosphatemia – Overview 8
Pipeline Products for Hyperphosphatemia – Comparative Analysis 9
Hyperphosphatemia – Therapeutics under Development by Companies 10
Hyperphosphatemia – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hyperphosphatemia – Products under Development by Companies 15
Hyperphosphatemia – Companies Involved in Therapeutics Development 16
Astellas Pharma Inc. 16
AstraZeneca PLC 17
Medice Arzneimittel Putter GmbH & Co. KG 18
Mitsubishi Tanabe Pharma Corporation 19
OPKO Health, Inc. 20
Panion & Bf Biotech Inc 21
Sanofi 22
Spectrum Pharmaceuticals, Inc. 23
Toray Industries, Inc. 24
Vifor Pharma AG 25
Hyperphosphatemia – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 32
Drug Profiles 34
ASP-3325 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
colestilan chloride – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Fe-SAMMS – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
fermagate – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ferric citrate – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
JPH-101 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
niacinamide – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
PT-20 – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
RDX-002 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
SPI-014 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
sucroferric oxyhydroxide – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
tenapanor hydrochloride – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
TRK-390 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
VS-501 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
VS-505 – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Hyperphosphatemia – Recent Pipeline Updates 57
Hyperphosphatemia – Dormant Projects 68
Hyperphosphatemia – Discontinued Products 69
Hyperphosphatemia – Product Development Milestones 70
Featured News & Press Releases 70
Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis 70
Jan 27, 2015: Velphoro receives Swissmedic approval for the treatment of hyperphosphatemia in adult patients with chronic kidney disease on dialysis 70
Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch 71
Dec 04, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Auryxia (ferric citrate) Covering Orally Administrable Forms 72
Nov 19, 2014: New Drug Application Submitted For PA21 (development code) For Treatment Of Hyperphosphatemia 73
Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate 74
Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study 74
Oct 23, 2014: Ardelyx’s Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology’s Kidney Week 2014 75
Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms 77
Sep 05, 2014: Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia 77
Appendix 79
Methodology 79
Coverage 79
Secondary Research 79
Primary Research 79
Expert Panel Validation 79
Contact Us 79
Disclaimer 80